Your browser doesn't support javascript.
loading
Imaging Markers in Genetic Forms of Parkinson's Disease.
Droby, Amgad; Thaler, Avner; Mirelman, Anat.
Affiliation
  • Droby A; Laboratory for Early Markers of Neurodegeneration (LEMON), Neurological Institute, Tel Aviv Medical Center, Tel Aviv 6801298, Israel.
  • Thaler A; Movement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv 6423906, Israel.
  • Mirelman A; Faculty of Medicine, Tel Aviv University, Tel Aviv 39040, Israel.
Brain Sci ; 13(8)2023 Aug 16.
Article in En | MEDLINE | ID: mdl-37626568
ABSTRACT
Parkinson's disease (PD) is a complex neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rigidity, and resting tremor. While the majority of PD cases are sporadic, approximately 15-20% of cases have a genetic component. Advances in neuroimaging techniques have provided valuable insights into the pathophysiology of PD, including the different genetic forms of the disease. This literature review aims to summarize the current state of knowledge regarding neuroimaging findings in genetic PD, focusing on the most prevalent known genetic forms mutations in the GBA1, LRRK2, and Parkin genes. In this review, we will highlight the contributions of various neuroimaging modalities, including positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI), in elucidating the underlying pathophysiological mechanisms and potentially identifying candidate biomarkers for genetic forms of PD.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Brain Sci Year: 2023 Type: Article Affiliation country: Israel

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Brain Sci Year: 2023 Type: Article Affiliation country: Israel